A Study of Tanezumab in Adults With Chronic Low Back Pain
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of multiple doses of
tanezumab administered every 8 weeks in treating chronic low back pain. Tanezumab is a
monoclonal antibody directed against human nerve growth factor.